Bioequivalence Study of Fixed-dose Combinations and Coadministered Individual Tablets of Saxagliptin/Metformin-Brazil

Key Inclusion Criteria: * Healthy men and women * women of childbearing potential who are using acceptable method of contraception * Women who are not pregnant or nursing * Body Mass Index (BMI) of 18 to 29.9 kg/m\^2, inclusive. BMI=weight(kg)/height(m)\^2. Key Exclusion Criteria: * Any significant acute or chronic medical illness. * History of gastrointestinal (GI) disease * Major surgery within 4 weeks of study drug administration * Any GI surgery that could impact study drug absorption * Donation of blood or plasma to a blood bank or in a clinical study (except a screening visit) within the 6 months of study drug administration. * Blood transfusion within 3 months of study drug administration for women and within 2 months for men * Inability to be venipunctured and/or tolerate venous access * Current smoker or recent (within 1 month) history of regular tobacco use * Recent (within 6 months of study drug administration) drug or alcohol abuse * Participation in a bioequivalence study within the last 6 months of study drug administration * Estimated creatinine clearance of \<80 mL/min using Cockcroft-Gault formula * History of allergy to drug class or related compounds * History of allergy to metformin or other similar acting agents * History of any significant drug allergy